SpyGlass Pharma Inc (SGP) Stock Analysis
Verdict: WATCH (do not buy)
Deep cash runway funds Phase 3 BIM-IOL trials into 2028, but pre-revenue clinical binary risks and EPS misses warrant patience.
Investment score: 48/100
Analysis as of
Is SpyGlass Pharma Inc stock worth reviewing? The TradeMates thesis
SpyGlass Pharma possesses a funded runway through 2028 following its $172.5M IPO and holds strong clinical Phase 1/2 data for its drug-eluting IOL system. However, as a pre-revenue biotech trading 26% off its 52-week highs with recent earnings misses, the model sees a neutral risk-reward balance until Phase 3 enrollment milestones approach.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
SpyGlass Pharma Inc opportunities and risks
What speaks for SGP
- Extended Cash Runway Into 2028
What speaks against SGP
- Binary Clinical Trial Readout Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SGP | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.2% |
| SPTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -4.9% |
| ANRO | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.0% |
| ALMS | n/a | 107.1x | n/a | 88.2% | -5933.5% | -44.4% |
| COLL | 15.2x | 0.9x | 3.1x | 60.0% | 5.9% | 43.5% |
| Peer median | n/a | 0.5x | n/a | 30.0% | 0.0% | -6.4% |
Frequently asked questions about SpyGlass Pharma Inc (SGP)
Is SGP stock a good investment?
The TradeMates model rates SpyGlass Pharma Inc as WATCH (do not buy) with an investment score of 48/100. SpyGlass Pharma possesses a funded runway through 2028 following its $172.5M IPO and holds strong clinical Phase 1/2 data for its drug-eluting IOL system. However, as a pre-revenue biotech trading 26% off its 52-week highs with recent earnings misses, the model sees a neutral risk-reward balance until Phase 3 enrollment milestones approach. This is algorithmic model output, not personal investment advice.
Is SGP stock a buy?
The TradeMates model verdict for SGP is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.